Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Adverse reactions
- 20 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 18 May 2017 Planned End Date changed from 8 Mar 2025 to 29 Mar 2025.
- 18 May 2017 Planned primary completion date changed from 8 Mar 2022 to 29 Mar 2022.